Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Invested Capital (2020 - 2025)

Roivant Sciences' Invested Capital history spans 6 years, with the latest figure at $4.3 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 22.88% year-over-year to $4.3 billion; the TTM value through Dec 2025 reached $4.3 billion, down 22.88%, while the annual FY2025 figure was $4.7 billion, 31.86% down from the prior year.
  • Invested Capital reached $4.3 billion in Q4 2025 per ROIV's latest filing, down from $4.8 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $7.0 billion in Q4 2023 to a low of $1.7 billion in Q3 2023.
  • Average Invested Capital over 5 years is $3.6 billion, with a median of $2.5 billion recorded in 2021.
  • Peak YoY movement for Invested Capital: soared 287.73% in 2023, then crashed 31.86% in 2025.
  • A 5-year view of Invested Capital shows it stood at $2.5 billion in 2021, then decreased by 26.48% to $1.8 billion in 2022, then skyrocketed by 287.73% to $7.0 billion in 2023, then fell by 20.78% to $5.5 billion in 2024, then fell by 22.88% to $4.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Invested Capital are $4.3 billion (Q4 2025), $4.8 billion (Q3 2025), and $4.8 billion (Q2 2025).